Advanced search
Publication Cover
OncoImmunology Volume 13, 2024 - Issue 1
Submit an article Journal homepage
0
Views
0
CrossRef citations to date
0
Altmetric
Comment

Targeted opening of the blood–brain barrier facilitates doxorubicin/anti-PD-1-based chemoimmunotherapy of glioblastoma

Jonathan G. Pola Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université de Paris Cité, Sorbonne Université, Inserm U1138, Institut Universitaire de France, Paris, France;b Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, Villejuif, FranceCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-8355-7562View further author information
ORCID Icon,
Manuela Lizarralde-Guerreroa Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université de Paris Cité, Sorbonne Université, Inserm U1138, Institut Universitaire de France, Paris, France;b Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, Villejuif, France;c Université Paris-Saclay, Faculté de Médecine, Kremlin-Bicêtre, FranceView further author information
,
Andrea Checcolia Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université de Paris Cité, Sorbonne Université, Inserm U1138, Institut Universitaire de France, Paris, France;b Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, Villejuif, France;d Université Paris Sciences et Lettres (PSL), Paris, FranceView further author information
&
Guido Kroemera Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université de Paris Cité, Sorbonne Université, Inserm U1138, Institut Universitaire de France, Paris, France;b Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, Villejuif, France;e Institut du Cancer Paris CARPEM, Department of Biology, Hôpital Européen Georges Pompidou, AP-HP, Paris, FranceCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-9334-4405View further author information
ORCID Icon
Article: 2385124 | Received 18 Jul 2024, Accepted 23 Jul 2024, Published online: 27 Jul 2024

References

  • Kroemer G, Chan TA, Eggermont AMM, Galluzzi L. Immunosurveillance in clinical cancer management. CA Cancer J Clin. 2024;74(2):187–3. doi:10.3322/caac.21818.
  • Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, Schmitt E, Hamai A, Hervas-Stubbs S, Obeid M, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med. 2005;202(12):1691–1701. doi:10.1084/jem.20050915.
  • Galluzzi L, Guilbaud E, Schmidt D, Kroemer G, Marincola FM. Targeting immunogenic cell stress and death for cancer therapy. Nat Rev Drug Discov. 2024;23(6):445–460. doi:10.1038/s41573-024-00920-9.
  • Agosti E, Zeppieri M, De Maria L, Tedeschi C, Fontanella MM, Panciani PP, Ius T. Glioblastoma immunotherapy: a systematic review of the present strategies and prospects for advancements. Int J Mol Sci. 2023;24(20):24. doi:10.3390/ijms242015037.
  • Sferruzza G, Consoli S, Dono F, Evangelista G, Giugno A, Pronello E, Rollo E, Romozzi M, Rossi L, Pensato U, et al. A systematic review of immunotherapy in high-grade glioma: learning from the past to shape future perspectives. Neurol Sci. 2024;45(6):2561–2578. doi:10.1007/s10072-024-07350-w.
  • Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, Baehring J, Ahluwalia MS, Roth P, Bähr O, et al. Effect of Nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol. 2020;6(7):1003–1010. doi:10.1001/jamaoncol.2020.1024.
  • Lim M, Weller M, Idbaih A, Steinbach J, Finocchiaro G, Raval RR, Ansstas G, Baehring J, Taylor JW, Honnorat J, et al. Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. Neuro Oncol. 2022;24(11):1935–1949. doi:10.1093/neuonc/noac116.
  • Kasenda B, Konig D, Manni M, Ritschard R, Duthaler U, Bartoszek E, Bärenwaldt A, Deuster S, Hutter G, Cordier D, et al. Targeting immunoliposomes to EGFR-positive glioblastoma. ESMO Open. 2022;7(1):100365. doi:10.1016/j.esmoop.2021.100365.
  • Arrieta VA, Gould A, Kim KS, Habashy KJ, Dmello C, Vazquez-Cervantes GI, Palacín-Aliana I, McManus G, Amidei C, Gomez C, et al. Ultrasound-mediated delivery of doxorubicin to the brain results in immune modulation and improved responses to PD-1 blockade in gliomas. Nat Commun. 2024;15(1):4698. doi:10.1038/s41467-024-48326-w.
  • Wendeln AC, Degenhardt K, Kaurani L, Gertig M, Ulas T, Jain G, Wagner J, Häsler LM, Wild K, Skodras A, et al. Innate immune memory in the brain shapes neurological disease hallmarks. Nature. 2018;556(7701):332–338. doi:10.1038/s41586-018-0023-4.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.